Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Approximately one third of patients with non–small-cell lung cancer (NSCLC) have stage III, locally advanced disease at diagnosis. The standard of care for patients with a good performance status and unresectable stage III NSCLC is platinum-based doublet chemotherapy concurrent with radiotherapy…

http://ift.tt/2wOIBCK